Tematyka naukowo-badawcza:

• Badania szlaku kinureninowego w chorobach nerek, układu krążenia.
• Zaburzenia metabolizmu kostnego, adipogenezy oraz funkcji śródbłonka i układu hemostazy w chorobach nerek.

Stosowane techniki badawcze:

• Techniki immunoenzymatyczne (ELISA).
• Techniki elektroforetyczne (Western immunoblot).
• Real-time PCR.

Programy realizowane w Zakładzie Farmakoterapii Monitorowanej:

Aktualne publikacje:

• Modulation of the Paracrine Kynurenic System in Bone as a New Regulator of Osteoblastogenesis and Bone Mineral Status in an Animal Model of Chronic Kidney Disease Treated with LP533401. Mor A, Pawlak K, Kalaska B, Domaniewski T, Sieklucka B, Zieminska M, Cylwik B, Pawlak D. Int J Mol Sci. 2020.
   

• Inhibition of peripheral serotonin synthesis by LP533401 and disturbances in calciotropic hormones attenuated excessive osteoblastogenesis with simultaneous improvement of bone mineral status in 5/6 nephrectomized rats. Pawlak D, Domaniewski T, Sieklucka B, Jakuc M, Pawlak K. Biochim Biophys Acta Mol Basis Dis. 2019.
   

• The use of LP533401 as a therapeutic option for renal osteodystrophy affects, renal calcium handling, vitamin D metabolism, and bone health in uremic rats. Pawlak D, Domaniewski T, Znorko B, Pawlak K. Expert Opin Ther Targets. 2019.
   

• The impact of antihypertensive pharmacotherapy on interplay between protein-bound uremic toxin (indoxyl sulfate) and markers of inflammation in patients with chronic kidney disease. Kaminski TW, Pawlak K, Karbowska M, Znorko B, Mor AL, Mysliwiec M, Pawlak D. Int Urol Nephrol. 2019.
   

• LP533401 restores bone health in 5/6 nephrectomized rats by a decrease of gut-derived serotonin and regulation of serum phosphate through the inhibition of phosphate co-transporters expression in the kidneys. Pawlak D, Znorko B, Kalaska B, Domaniewski T, Zawadzki R, Lipowicz P, Doroszko M, Łebkowska U, Grabowski P, Pawlak K. Bone. 2018.
   

• RANKL/OPG system regulation by endogenous PTH and PTH1R/ATF4 axis in bone: Implications for bone accrual and strength in growing rats with mild uremia. Znorko B, Pawlak D, Oksztulska-Kolanek E, Domaniewski T, Pryczynicz A, Roszczenko A, Rogalska J, Lipowicz P, Doroszko M, Brzoska MM, Pawlak K. Cytokine. 2018.
   

• Elevated Levels of Peripheral Kynurenine Decrease Bone Strength in Rats with Chronic Kidney Disease. Kalaska B, Pawlak K, Domaniewski T, Oksztulska-Kolanek E, Znorko B, Roszczenko A, Rogalska J, Brzoska MM, Lipowicz P, Doroszko M, Pryczynicz A, Pawlak D. Front Physiol. 2017.
   

• The impact of peripheral serotonin on leptin-brain serotonin axis, bone metabolism and strength in growing rats with experimental chronic kidney disease. Pawlak D, Domaniewski T, Znorko B, Oksztulska-Kolanek O, Lipowicz P, Doroszko M, Karbowska M, Pawlak K. Bone 2017.
   

• A link between central kynurenine metabolism and bone strength in rats with chronic kidney disease. Kalaska B, Pawlak K, Oksztulska-Kolanek E, Domaniewski T, Znorko B, Karbowska M, Citkowska A, Rogalska J, Roszczenko A, Brzoska MM, Pawlak D. PeerJ. 2017.
   

• Serum metabolic fingerprinting after exposure of rats to quinolinic acid. Kalaska B, Ciborowski M, Domaniewski T, Czyzewska U, Godzien J, Miltyk W, Kretowski A, Pawlak D. J Pharm Biomed Anal. 2016.
   

• Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts.Tankiewicz-Kwedlo A, Hermanowicz J, Surażynski A, Rożkiewicz D, Pryczynicz A, Domaniewski T, Pawlak K, Kemona A, Pawlak D. Mol Cell Biochem. 2016.
   

• The Biomechanical Testing for the Assessment of Bone Quality in an Experimental Model of Chronic Kidney Disease. Oksztulska-Kolanek E, Znorko B, Michałowska M, Pawlak K. Nephron. 2016

   

Dorobek naukowy:

• prof. dr hab. Krystyna Pawlak
• dr hab. Anna Tankiewicz-Kwedlo